Local management of pancreatic carcinoma: Iodine-125 implantation

Goertz, Sanne; Ali, Mapar Mohammad; Parker, George A.

doi:10.1016/s0936-6555(05)80214-6

Cited by 13 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early in the 1990s, intraoperative brachytherapy was introduced for its improvement on the survival time in patients who received palliative surgery. 3,4 Other ways to input radioactive seeds in the solid tumor include computerized tomography (CT) 5,6 or ultrasound-guided methods. 7 Advances in image-guided placement of the seeds have enabled physicians to use CT or ultrasound to deliver conformal radiation doses to the tumor tissue, resulting in improved success rates for the local control and significant sparing of the surrounding normal tissues.…”

Section: Introductionmentioning

confidence: 99%

Endoscope-assisted brachytherapy for pancreatic cancer: From tumor killing to pain relief and drainage

Du¹,

Li²,

Jin³

2011

jig

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Endoscope-assisted brachytherapy for pancreatic cancer: From tumor killing to pain relief and drainage

Du¹,

Li²,

Jin³

2011

jig

View full text Add to dashboard Cite

“…Direct implantation of radioactive sources enables the delivery of intensive but localized doses of radiation which, when combined with external beam radiation therapy and chemotherapy, has been found to produce significant improvements in local disease control. One study 144 found that implantation led to enhanced survival ( Table 3), and significantly improved local control of the disease and effective palliation of symptoms. Unfortunately, radioactive implantation is associated with complications such as deep vein thrombosis, gastrointestinal haemorrhage and sepsis and also exhibits an operative mortality as high as 33% 153 .…”

Section: The Role Of Radiotherapy or Chemoradiotherapymentioning

confidence: 99%

Review article: current treatment and optimal patient management in pancreatic cancer

Haycox

Lombard

Neoptolemos

et al. 1998

Aliment Pharmacol Ther

View full text Add to dashboard Cite

This review analyses the current state of knowledge and understanding concerning the optimum treatment and therapeutic management of patients who suffer from pancreatic cancer. It outlines recent advances in scientific understanding and assesses their potential future value to clinicians in confronting this disease. Despite a significant expansion in scientific knowledge relating to factors underlying the early development of pancreatic carcinoma, the clinician continues to be restricted to a severely limited therapeutic armoury for this disease. Local therapies (surgery and radiation) are inevitably of limited value in the face of a disease that is normally encountered at a stage where metastasis is already highly developed. Despite such limitations, however, surgery performed in specialist units may be of value for 10-20% of patients, with a 5-year survival rate in such units of between 10 and 24%. This may be improved even further by appropriate use of adjuvant treatment. The advanced stage of the disease when normally encountered emphasizes the potential value of systemic treatment in this therapeutic area. Unfortunately systemic treatment (chemotherapy) has been found to be ineffective to date in significantly extending survival, with a low rate and duration of remission being identified in most trials. The challenge for both the health service and the pharmaceutical industry is to harness recent and future developments in scientific knowledge to the practical benefit of clinicians. Where cure is possible it should be vigorously pursued; where it is not, in this field above all others, clinicians have a duty of care. To achieve this it is necessary to abandon the therapeutic nihilism that has characterized the attitudes of clinicians towards this disease in the past. It is time that such nihilism was replaced by a recognition of the challenges and the opportunities available to clinicians in enhancing the quantity and quality of life available to patients. The dictum of 'curing whenever possible but caring always' should be the future therapeutic philosophy used to guide clinicians in this important and rapidly changing therapeutic area.

show abstract

“…[9][10][11][12][13] Trials and commercialization of brachytherapy treatments and devices utilizing radioisotopes of phosphorus-32 (P-32), iodine, gold, iridium, and yttrium have been undertaken. [13][14][15][16][17][18] However, none of these radioactive agents has entered routine clinical practice.…”

Section: Introductionmentioning

confidence: 99%

An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol

Bhutani¹,

Klapman

Tuli

et al. 2020

Endosc Ultrasound

View full text Add to dashboard Cite

Current treatment options for patients with unresectable locally advanced pancreatic cancer (LAPC) include chemotherapy alone or followed by chemoradiation or stereotactic body radiotherapy. However, the prognosis for these patients remains poor, with a median overall survival <12 months. Therefore, novel treatment options are needed. Currently, there is no brachytherapy device approved for pancreatic cancer treatment. Hereby, we present the protocol of a prospective, multicenter, interventional, open-label, single-arm pilot study (OncoPac-1, Clinicaltrial.gov-NCT03076216) aiming to determine the safety and efficacy of Phosphorus-32 when implanted directly into pancreatic tumors using EUS guidance, for patients with unresectable LAPC undergoing chemotherapy (gemcitabine ± nab-paclitaxel).

show abstract

Local management of pancreatic carcinoma: Iodine-125 implantation

Cited by 13 publications

References 12 publications

Endoscope-assisted brachytherapy for pancreatic cancer: From tumor killing to pain relief and drainage

Endoscope-assisted brachytherapy for pancreatic cancer: From tumor killing to pain relief and drainage

Review article: current treatment and optimal patient management in pancreatic cancer

An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol

Contact Info

Product

Resources

About